Abbott launches 14 valent Pneumococcal Conjugate Vaccine (PCV-14) That Offers Broadest Protection for Children Against Pneumococcal Bacterial Infections
Abbott, the global healthcare leader, announced today the launch of its Pneumococcal Conjugate Vaccine, PneumoShield 14, for children over 6 weeks of age. Abbott’s PCV-14 valent (Pneumococcal Conjugate Vaccine), offers broad protection, covering the highest number of serotypes, or strains, as compared to existing PCV-10 and PCV-13 vaccines.